Today's Date: March 29, 2024
Parkland Corporation Announces the Results of the 2024 Annual General Meeting of Shareholders   •   Visit Visalia Recognizes Autism Awareness Month in April   •   Empire State Realty Trust Receives WELL Health-Safety Leadership Award; Becomes Among the First Commercial Office and Multifamil   •   National University Receives 2024 Military Friendly® Gold Designation   •   Chosgo K23: One of the Best Bluetooth Hearing Aids for Seniors   •   Make-A-Wish and celebrity wish granters announce goal to recruit 1 million people to become "WishMakers"   •   e.l.f. Cosmetics Debuts TikTok Shop Super Brand Day   •   Jamieson Wellness Publishes Inaugural Sustainability Impact Report   •   Anaergia Announces Escrow Closing of Second Tranche of the Strategic Investment   •   Anaergia Announces Delay in the Filing of Its Audited Financial Statements and Related Disclosures   •   YMCA of the USA Partners With Old Spice To Increase High School Graduation Among Boys And Young Men Of Color Through Mentorship   •   Syngenta Group reports $32.2 billion sales and $4.6 billion EBITDA in 2023   •   Coachella Concerned That People Have Sex, Says AHF   •   Re:wild and Colossal Biosciences team up to leverage revolutionary technology to save critically endangered species on the brink   •   Midea Group releases its first-ever ESG brand story with an unexpected VIP visit highlighting its commitment to sustainability.   •   Fosun Management on 2023 Annual Results: Focusing on Core Industries with Established Advantages   •   Amerex Group Unveils Red Carter Swimwear's Revitalized Collection   •   Sypher Secures Strategic Partnership with FAIA to Fuel Growth   •   Equalpride Partners with TransLash Media for Trans Day of Visibility, Amplifying Voices of Black Trans Femmes in the Arts   •   VIRGIN HOTELS CHAMPIONS INCLUSIVE TRAVEL FOR NEURODIVERSE TRAVELERS
Bookmark and Share

EpimAb Biotherapeutics Appoints Yonghong Zhu, M.D., Ph.D., as Chief Medical Officer

SHANGHAI, China , June 08 /Businesswire/ - EpimAb Biotherapeutics, a clinical stage biotechnology company specializing in the development of bispecific antibodies, today announced the appointment of Yonghong Zhu, M.D., Ph.D., as Chief Medical Officer (CMO). As CMO, Dr. Zhu will be responsible for overseeing all clinical development activities for the company’s clinical stage assets. This strategic addition to the executive team further strengthens the company's commitment to innovation and mission of advancing cutting-edge bispecific therapies. Dr. Zhu replaces EpimAb’s previous CMO, Dr. Bin Peng, who recently retired from EpimAb after five years of service at the company.

With around two decades of experience in the biotech industry, Dr. Zhu brings an outstanding track record and expertise that spans across early to late-stage development in oncology and immunology to EpimAb. Before joining EpimAb, Dr. Zhu was the CMO at MaxiNovel Pharmaceuticals, and prior to this, he held leadership positions in Clinical Development and Translational Medicine at Roche, Takeda and Henlius, where he made significant contributions to developing and executing overall clinical strategies, and evaluating and driving strategic collaborations. Dr. Zhu obtained his Bachelor’s and Medical Degrees (combined 7 year program) at Nanjing University Medical School, and completed his Ph.D. training in Microbiology & Immunology (Major in Virology) at the University of Rochester School of Medicine & Dentistry.

"We are excited to welcome Dr. Zhu as our new Chief Medical Officer," said Dr. Chengbin Wu, Founder and CEO of EpimAb. "His extensive knowledge in the oncology and immunology fields, plus a wealth of experience designing and leading early and late-stage clinical programs align perfectly with our vision. We are confident that Dr. Zhu's leadership skills and expertise will accelerate our mission of developing breakthrough therapies for diseases with significant unmet need."

Dr. Zhu commented, "I am honored to join and collaborate with the dedicated team at EpimAb. With its multiple proprietary and unique platform technologies and an exceptional R&D team, EpimAb has generated several differentiated clinical programs with tremendous potential. I look forward to further advancing these programs and contributing to the future success of the company.”

About EpimAb Biotherapeutics

EpimAb Biotherapeutics is a clinical stage biopharmaceutical company specializing in the development of multispecific antibodies. Utilizing our broad range of in-house research and technology capabilities, including the proprietary FIT-Ig® (Fabs-In-Tandem Immunoglobulin) and MAT-Fab (Monovalent Asymmetric Tandem Fab) bispecific platforms, EpimAb is generating and globally advancing a unique pipeline of transformative preclinical and clinical assets that aim to benefit cancer patients. For further information, please visit: www.epimab.com


STORY TAGS: Personnel, Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Other Health, China, Asia Pacific,

Video

White House Live Stream
LIVE VIDEO EVERY SATURDAY
alsharpton Rev. Al Sharpton
9 to 11 am EST
jjackson Rev. Jesse Jackson
10 to noon CST


Video

LIVE BROADCASTS
Sounds Make the News ®
WAOK-Urban
Atlanta - WAOK-Urban
KPFA-Progressive
Berkley / San Francisco - KPFA-Progressive
WVON-Urban
Chicago - WVON-Urban
KJLH - Urban
Los Angeles - KJLH - Urban
WKDM-Mandarin Chinese
New York - WKDM-Mandarin Chinese
WADO-Spanish
New York - WADO-Spanish
WBAI - Progressive
New York - WBAI - Progressive
WOL-Urban
Washington - WOL-Urban

Listen to United Natiosns News